You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)
|
|---|---|
| Published in |
Frontiers in oncology, March 2023
|
| DOI | 10.3389/fonc.2023.1136221 |
| Pubmed ID | |
| Authors |
Marinda Meertens, M. Benthe Muntinghe-Wagenaar, Barend J. Sikkema, Marta Lopez-Yurda, Valesca P. Retèl, Marthe S. Paats, Rob Ter Heine, Ed Schuuring, Wim Timens, Daan J. Touw, Job F. M. van Boven, Adrianus. J. de Langen, Sayed M. S. Hashemi, Lizza E. L. Hendriks, Sander Croes, Michel M. van den Heuvel, Anne-Marie C. Dingemans, Ron H. J. Mathijssen, Egbert F. Smit, Alwin D. R. Huitema, Neeltje Steeghs, Anthonie J. van der Wekken |
X Demographics
The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 7% |
| Germany | 1 | 7% |
| Italy | 1 | 7% |
| United Kingdom | 1 | 7% |
| Spain | 1 | 7% |
| Unknown | 10 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 12 | 80% |
| Practitioners (doctors, other healthcare professionals) | 2 | 13% |
| Scientists | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 16 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 1 | 6% |
| Student > Bachelor | 1 | 6% |
| Student > Master | 1 | 6% |
| Unknown | 13 | 81% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 6% |
| Sports and Recreations | 1 | 6% |
| Medicine and Dentistry | 1 | 6% |
| Unknown | 13 | 81% |
Attention Score in Context
This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 December 2023.
All research outputs
#1,534,151
of 26,171,302 outputs
Outputs from Frontiers in oncology
#275
of 22,919 outputs
Outputs of similar age
#31,834
of 431,149 outputs
Outputs of similar age from Frontiers in oncology
#8
of 1,387 outputs
Altmetric has tracked 26,171,302 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,919 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 431,149 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 1,387 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.